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ABSTRACT 
Objective: In this study, we investigated the hepatoprotective activity of Turmesac® on Human liver cells (HepG2 cell line) and anti-inflammatory 
effect on Murine macrophages (Raw 264.7 cell line) by flow Cytometry.  
Methods: Cell viability of HepG2 and Raw 264.7 cells determined by the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] 
assay to identify a non-cytotoxic concentration of Turmesac® for the respective cell lines after 24 h exposure period. Further hepatoprotective 
effect of Turmesac® was performed in H2O2 treated liver cells using H2DCF-DA staining by flow cytometry. The anti-inflammatory potency of 
Turmesac® was evaluated in Lipopolysaccharide (LPS 2µg/ml) stimulated Murine Raw 264.7 macrophages by measuring the relative fluorescence 
intensity of 2 cytokines, Interleukin-8(IL-8) and (Interleukin-12) IL-12 by flow cytometric analysis. 
Results: Turmesac® concentrations of less than 50μg/ml did not show significant cytotoxicity on both HepG2 and Raw 264.7, cell lines following 
the treatment period of 24 h and selected 50μg/ml as the optimum concentration for hepatoprotective and anti-inflammatory models. The reactive 
oxygen species (ROS) study revealed that Turmesac® (50μg/ml) effectively suppressed the H2DCF-DA expression in HepG2 cells. Secondly, 
Turmesac® significantly suppressed the anti-inflammatory cytokine expressions of IL-8 and IL-12 in LPS pre-stimulated cells categorising as a 
potentially potent anti-inflammatory drug. The mean fluorescence intensity percentage of IL-8 is control 8.86, LPS 50.49, Turmesac® 19.63 and 
IL12 is control 10.41, LPS 68.94, and Turmesac® 15.79 respectively.  
Conclusion: This study highlighted that Turmesac® could be considered as a promising hepatoprotective and anti-inflammatory compound and a 
therapeutic agent in curing liver-related and inflammation-related diseases.  
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INTRODUCTION 
Traditional medicine can be traced back centuries, with some of 
these still being used for treatments and have become the current 
focus of research in treating the various diseases and ailments seen 
today [1-2]. Turmeric is a spice that comes from the root Curcuma 
longa, a member of the ginger family Zingiberaceae. Curcumin has a 
long history of administration in the traditional medicine of India, 
China and Iran, and it has been used in different people for the 
treatment of many diseases such as diabetes, liver disease, 
rheumatoid diseases, atherosclerosis, infectious diseases and 
cancers [3]. In the ancient Indian medicine, Ayurveda, a topical agent 
made of turmeric paste has been used to treat common ocular 
infections and inflammations; it has also been used in wound 
dressing in conditions such as bites, burns, and some other skin 
diseases [4]. Curcuminoids are components of turmeric, which 
include mainly curcumin (diferuloylmethane), demethoxycurcumin, 
and bisdemethoxycurcumin. Curcumin, a polyphenol, has been 
shown to target multiple signaling molecules/pathways while also 
demonstrating activity at the cellular level, which has helped to 
support its multiple health benefits [5], metabolic syndromes [6], 
and to help in the management of inflammatory and degenerative 
eye conditions [7,  8]. In addition, it has been shown to benefit the 
kidneys [9]. While there appears to be countless therapeutic benefits 
to curcumin supplementation, most of these benefits are due to its 
antioxidant and anti-inflammatory effects [5, 10]. It has shown very 
strong antioxidant and anti-inflammatory properties that has vast 
research coverage in various human and animal cell lines, models 
and trials. Inflammation and oxidative activity are usually triggered 
during a stressful event or an imbalance in these systems. Reactive 
oxygen species (ROS) are a by-product of normal cellular respiration 
and is mainly involved in cellular damage. Previous in vitro, animal 
models and clinical trials have shown that curcumin is a potent 
nonsteroidal anti-inflammatory agent whose efficacy is as powerful 
as known steroidal and nonsteroidal (indomethacin and 
phenylbutazone) agents [11, 12]. Curcumin has been shown to 
inhibit macrophage-derived cytokines like IL-8, monocyte 
inflammatory protein-1 and tumor necrosis factor α [13]. Therefore, 
the aim of this study, we investigated the hepatoprotective activity 
of Turmesac® on Human liver cells (HepG2) and anti-inflammatory 
effect on Murine macrophages (Raw 264.7) by flow cytometry. 
MATERIALS AND METHODS 
Preparation of sample  
Turmesac® is manufactured and registered by Star Hi Herbs Pvt. 
Ltd, Jigani, Bangalore, Karnataka, India 
Cell lines and chemicals  
The Raw 264.7 Murine macrophage cell line and HepG2 Human 
hepatocellular carcinoma cell lines were procured from National 
Centre for Cell Science, NCCS, Pune, Maharshtra, India. DMEM with 
high glucose (Cat No. AL111), FBS (Cat No. RM10432), Antibiotic-
Antimycotic solution (Cat No. A002) were purchased from Hi-Media 
laboratories, Mumbai, India. Lipopolysacchride (LPS) and Hydrogen 
Peroxide (H2O2) were of molecular biology grade procured from 
Sigma Aldrich, USA. H2DCFDA (D-399) and MTT reagent (M6494) 
purchased from Thermo Fisher Scientific (Gibco, USA). Flow 
Cytometry oriented reagents viz., PE Mouse Anti-Human IL-8 
antibody (Cat No.554720) and PE Mouse Anti-Human IL-12 antibody 
(Cat No. 559329) were procured from the BD Biosciences, USA, CA. 
Cell culture and treatment 
Raw 264.7 and HepG2 cell lines grown in DMEM high glucose medium 
supplemented with 10% FBS, 100 µl of Antibiotic-Antimycotic (100X) 
in a CO2 incubator at 37 °C with 20% oxygen and 5% CO2 in saturated 
humidity. Post 24hr seeding event, the medium was changed prior to 
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treatment with Turmesac® and H2O2 or LPS. Turmesac® and 
H2O2/lPS were dissolved in DMSO and vortexed to ensure 100% 
solubility. The final concentration of DMSO added to the cell culture 
medium was below 0.1%. The final Turmesac® concentrations added 
to the cell culture medium ranging from 6.25-100µg/ml, respectively. 
A 0.1% DMSO concentration was used as a Vehicle control, which does 
not exhibit any cytotoxicity on both the cells.  
MTT assay  
An MTT assay was performed to evaluate the HepG2 and Raw 264.7 
cell viability. 20,000 cells per well were seeded in 96 well plate and 
treated with 6.25, 12.5, 25, 50 and 100 µg/ml of Turmesac® for 24 h 
to determine the optimum concentration for further studies. Post 
incubation period, remove the spent media and add 100 µl of 0.5 
mg/ml MTT reagent for 4 h at 37 °C, the formazan crystals generated 
due to the reduction of MTT by metabolically active cells. They were 
released from the cells and dissolved using 100 µl DMSO (Sigma-
Aldrich, USA). In MTT assay, formazan accumulation directly reflects 
the mitochondrial activity in the live cells, which is an indirect 
measurement for the cell viability [14]. The plate was agitated on a 
gyratory shaker for 10-20 min and the absorbance was measured at 
570 nm with an ELISA microplate reader (Biotek, USA). The 
percentage of cell viability is calculated using the below formula:  
 
Hepatoprotective activity 
Hepatoprotective effect of Turmesac® on HepG2 cells was evaluated 
by ROS activity through flow cytometric analysis. Cell-permeant 2, 7-
dichlorodihydrofluorescein diacetate (H2DCF-DA) is a widely used 
ROS indicator. The reduced non-fluorescent fluorescein H2DCF-DA 
can be oxidized and converted into fluorescent 2, 7-
dichlorofluorescein (DCF) by intracellular ROS. HepG2 cells were 
seeded at a density of 0.5 x 106cells/1 ml of medium per well in a 6-
well plate (Biolite-Thermo) and incubated at 37 °C in a humidified 
incubator for 24 h. The medium was removed and washed with 1 x 
PBS. Cells were pre-treated with H2O2 (200 µM) for 3 h to induce 
stress on cells and further treated with Turmesac® with the 
concentration of 50µg/ml for test group by leaving controls and 
incubated for 24 h at 37 °C. After the incubation period, collect the 
supernatant and cells into sterile tubes and centrifuged at 300 × g 
for 5 min at room temperature. The pellets were washed twice with 
1 x PBS and cells were stained with 10µM of H2DCF-DA and incubate 
for 30 min at 37 °C in the dark. Further cells are centrifuged at 300 × 
g and resuspend the pellet with 400 µl of DPBS. Fluorescence of 
H2DCF-DA was measured by flow cytometry at a laser excitation of 
485/535 nm using Cell Quest Pro software version 6. 
Anti-inflammatory activity 
For the evaluation of anti-inflammatory activity, Raw 264.7 cells were 
cultured in a 6 well plate and treated with 3 different culture 
conditions viz., LPS (2ug/ml), LPS (2µg/ml)+Turmesac® (50μg/ml) 
and untreated without any treatment. Briefly, the cells were pre 
stimulated with 2 µg/ml of LPS for 3 h to induce inflammation and 
following stimulation, the cells were either treated with 50µg/ml of 
Turmesac® or LPS stimulated alone (negative control) with 2 ml 
DMEM medium. Cells were incubated for 24 h and harvested into 
centrifuge tubes (BD Biosciences) and centrifuged at 300 × g for five 
minutes in a Remi: R-8 °C centrifuge and were washed twice with D-
PBS. The pelleted cells were incubated at room temperature with 0.5 
ml BD Cytofix/Cytoperm for 10 min and washed with 0.5% Bovine 
Serum Albumin solution (1x PBS and 0.1% sodium azide). Cells were 
incubated with 20μl of PE-Mouse Anti Human interleukin 8 (IL-8) 
antibody/Anti Human IL-12 separately for 30 min in the dark at 25 °C 
and expression measured using a BD FACS Calibur flow cytometer (BD 
Biosciences) and data analyzed by Cell Quest Pro software version 6. 
Statistical analysis 
All the data were analyzed using Microsoft Excel 2007 version in 
creating graphical representation of the mean with calculated 
standard errors. Flow Cytometric data was analyzed using Cell Quest 
Pro software version 6. 
 
Table 1: % of cell viability values turmesac® towards HepG2 and Raw 264.7 cells at 24 h as determined by MTT assay 
Cell line/Concentration 0 6.25 12.5 25 50 100 
 HepG2 100 87.32246 91.21515 94.79221 98.79011 99.36875 
Raw 264.7 100 97.56543 94.09617 90.44431 79.18442 63.42057 
 
 
Fig. 1: The percentage viability of HepG2 and raw 264.7 cells treated with various concentrations of turmesac® for 24 h as determined by 
MTT assay 
Firoz et al. 





Fig. 2: Representative flow cytometry histograms of total intracellular ROS levels (H2DCF-DA) in HepG2 cells prestimulated with H2O2 (24 




Fig. 3: Flow cytometry histograms of mean pro-inflammatory cytokines (IL-8 and IL-12) in Raw 264.7 cells pre-stimulated with LPS 
followed by 24 h exposure to Turmesac®. LPS served as a positive control (n=3, mean±standard error) 
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RESULTS AND DISCUSSION 
MTT cell viability assay 
The MTT cytotoxicity study of Turmesac® on human liver and 
murine cells lines was evaluated by colorimetry. Various 
concentrations were used to evaluate the toxicity of Turmesac® and 
the IC50 concentration was calculated from the resultant dose-
response curve. The relative Turmesac® cytotoxicity on HepG2 and 
Raw 264.7 cell lines are depicted in table 1. Turmesac® exhibited no 
cytotoxic effect on both HepG2 and Raw 264.7 cells at 
concentrations of and below 50μg/ml. On Raw 264.7 cell line, 
Turmesac® exhibited cytotoxicity at a concentration of 100μg/ml. 
Therefore, the non-cytotoxic concentration of 50µg/ml was selected 
for both cell lines for further mechanistic studies. 
Hepatoprotective activity by reactive oxygen species (ROS) 
Flow cytometry analysis using H2DCFDA-based staining study of ROS 
level in HepG2 cells revealed that H2O2 caused oxidative stress in 
HepG2 cells by inducing production of high levels of ROS. The 
generation of ROS within cells plays a major role in apoptosis. Hence, 
we evaluated the Turmesac® dependent intracellular ROS 
generation in HepG2 cells. The relative mean DCF fluorescence 
intensity value was very high in the H2O2 alone treated cells (52.5) 
due to heavy cell damage/apoptosis. However, post H2O2 exposure 
followed by Turmesac® treatment exhibited lower mean DCF 
fluorescence intensity (14.43). The Turmesac® treated cells’ 
observed mean DCF fluorescence intensity value was more than the 
control cells (7.72) and lower than the H2O2 treated cells (Fig.1 and 
2). This suggests that Turmesac® having negligible influence in 
generating intracellular ROS but rather suppresses the toxic potency 
of H2O2. This finding indicates that Turmesac® might exert its 
protective potency via a ROS-independent mechanism in HepG2 cells 
[15]. Showed that L-6 myoblast cells treated with 4 µM curcumin 
completely suppressed oxidation of H2DCF-DA. They had mentioned 
that, this indicates curcumin can easily diffuse through cellular 
membranes to elicit its effects by acting as a strong radical 
scavenging agent in the polar intracellular environment [15]. Nitric 
oxide production which is another contributor to oxidative stress 
[13, 16], can combine with superoxide to create a more damaging 
oxidant, peroxynitrate [17]. In vitro studies have shown that 
curcumin also strongly inhibits nitric oxidative stress [13, 16], can 
combine. Furthermore, a study by [18] showed turmeric had the 
highest scavenging activity when compared to other natural 
antioxidants, ginger, white saffron and temulawak. While curcumin 
alone had the second highest activity. We have previously shown 
that Turmesac® exhibited hepatoprotective properties in MCF-7 
cells at a concentration of 235.04 µg/ml [19]. 
Anti-inflammatory activity 
Turmesac® exhibits significant anti-inflammatory effect through IL-
8 and IL-12 inhibition in LPS stimulated macrophage cells. LPS-
induced inflammation, in in vitro cell lines and in animals, represents 
a standard paradigm for studying inflammation. IL-8 and IL-12 are 
the pro-inflammatory cytokines that are expressed drastically in 
cells exhibit more inflammation. The current study shows, the ability 
of Turmesac® to elicit anti-inflammatory effects on RAW 264.7 cells 
by evaluating pro-inflammatory cytokines, IL-8 and IL-12, 
expression. In the untreated cells, the relative interleukin expression 
is very low for both cytokines (fig. 3). On the other hand, LPS 
stimulated cells alone, exhibited 5-6 times higher expression than 
the untreated group. However, the Turmesac® treated cells 
following LPS stimulation were expressing lower expressions than 
the LPS alone treated cells. The mean fluorescence intensity 
percentage of IL-8 control 8.86, LPS 50.49, Turmesac® 19.63 and 
IL10 control 10.41, LPS 68.94 and Turmesac® 15.79. In vitro studies 
have shown that curcumin inhibits inflammation in mouse fibroblast 
cell line [13, 16]. Turmesac® showed a substantial inhibitory effect 
on pro-inflammatory cytokine production, IL-8 and IL-12. Curcumin 
has been shown to inhibit macrophage-derived cytokines like IL-8, 
monocyte inflammatory protein-1 and tumor necrosis factor α [13]. 
At a concentration of 20 µM, curcumin showed pro-inflammatory 
cytokine inhibition of IL-8 in adult peripheral mononuclear 
monocyte cells and preterm lung inflammatory cells and IL-12, 
thereby preventing allergic encephalomyelitis in T-lymphocytes 
[12]. Kerotinocytes treated with 6.7 µg/ml curcumin showed 
attenuated levels of IL-8 and the researchers believed that it could 
be used as a short-term treatment in type 2 diabetic nephropathy 
[5]. A study by [16] showed in LPS stimulated mouse splenocytes 
there was potent inhibitory release of IL-12 when treated with 0.8 to 
100 µg/ml of curcumin extract. Human phase one trial has shown 
patients and animal models administered with a daily curcumin 
intake between 1125-8000 mg/day showed no cytotoxic effect and 
exhibited anti-inflammatory effects through various target 
molecules including IL-12 [2]. Thus Turmesac® inhibited the 
expression of pro-inflammatory cytokines in LPS stimulated 
macrophages. 
CONCLUSION 
In conclusion, Turmesac® possesses biological actions in cell 
proliferation, suppression of ROS expression in H2O2 treated HepG2 
cells and inhibiting the expression of pro-inflammatory cytokines in 
LPS stimulated murine macrophages. This study’s results 
significantly indicated that Turmesac® is a potent and promising 
natural compound for the treatment of liver and inflammatory 
related diseases. The current work innovatively illustrated the 
hepatoprotective and anti-inflammatory expression studies through 
flow cytometric analyses.  
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